Company Overview
Snapshot
Founded in November 2016 by David Abargel and Michael Lyons, Triso operates with 11–50 employees. The company has secured funding across three rounds, including a grant from the Israel Innovation Authority in July 2020.
Business overview
Triso develops a platform for the automatic analysis and evaluation of anatomic images, serving a variety of medical disciplines. Its software accurately determines and defines the boundaries of anatomic features from ultrasounds, CTs, and X-rays. The company's patented imaging platform includes two modalities: LV-Tricardio, a fully automated echocardiogram imaging platform, and TriAngeo, which automatically traces arterial networks from angiogram images. Triso operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics, targeting healthcare providers in markets such as the United States.
Log in to access full profile ›Company Intelligence Q&A
- When was Triso founded?
- Triso was founded in November 2016.
- Who are the founders of Triso?
- Triso was founded by David Abargel and Michael Lyons.
- What is Triso's primary focus?
- Triso focuses on developing a platform for the automatic analysis and evaluation of anatomic images, applicable across various medical disciplines.
- What are Triso's main products?
- Triso's main products include LV-Tricardio, a fully automated echocardiogram imaging platform, and TriAngeo, which automatically traces arterial networks from angiogram images.
- Has Triso received any grants?
- In July 2020, Triso received a grant from the Israel Innovation Authority. In March 2017, Triso also received a grant from KamaTech.